Path: ...!newsreader4.netcologne.de!news.netcologne.de!peer01.ams1!peer.ams1.xlned.com!news.xlned.com!peer01.ams4!peer.am4.highwinds-media.com!news.highwinds-media.com!feeder1.feed.usenet.farm!feed.usenet.farm!eternal-september.org!news.eternal-september.org!.POSTED!not-for-mail
From: Olivier @ <olivier@monarobase.it>
Newsgroups: fr.bio.medecine
Subject: Re: =?ISO-8859-15?Q?Les_conseils_d'un_cardiologue_pour_une_bonne_?=
	=?ISO-8859-15?Q?sant=E9_cardiaque_[Re:_[Rappel]_(Etait:_Re:_Surmortalit?=
	=?ISO-8859-15?Q?=E9_2022_:_l'Insee_montre_que_les_jeunes_meurent_trop_!)]?=
Date: Mon, 12 Jun 2023 21:30:23 +0200
Organization: A noiseless patient Spider
Lines: 20
Message-ID: <u67rof$370tc$1@dont-email.me>
References: <6482a2ab$0$3090$426a34cc@news.free.fr> <mn.4a3c7e76364f9e54.119180@invalid.pasdepub> <u5vg5t$1uglo$2@dont-email.me> <mn.4c277e76a349e827.119180@invalid.pasdepub> <u5vj2r$1ulo6$4@dont-email.me> <1PIJY2R62_VIDwjJahNyIY-xCDU@jntp> <u5vmv8$1v8cs$1@dont-email.me> <u600o9$20d55$1@dont-email.me> <u6068m$2127r$1@dont-email.me> <u60715$214e7$1@dont-email.me> <u61660$27r4v$1@dont-email.me> <u618ct$2844f$1@dont-email.me> <6485acd6$0$24799$426a34cc@news.free.fr> <u64ao7$2mf6v$1@dont-email.me> <u66o81$32q6m$1@dont-email.me> <u67iq1$35tk7$1@dont-email.me> <64876546$0$7641$426a74cc@news.free.fr>
MIME-Version: 1.0
Content-Type: text/plain; charset="iso-8859-15"; format=flowed
Content-Transfer-Encoding: 8bit
Injection-Date: Mon, 12 Jun 2023 19:30:23 -0000 (UTC)
Injection-Info: dont-email.me; posting-host="72696ce54bdcfe3d1de48634e4d5f3c2";
	logging-data="3376044"; mail-complaints-to="abuse@eternal-september.org";	posting-account="U2FsdGVkX1/rRIxG327lzvdVnyptIGgd"
Cancel-Lock: sha1:ge9AQCPrj0GypGNFd963GpNfWrw=
X-Newsreader: MesNews/1.08.06.00
X-Received-Bytes: 2885
Bytes: 3021

Dans son message précédent, Le très gentil Luciole135 a écrit :

> Évidemment tous les auteurs ont des conflits d'intérêts à ce sujet avec les 
> industriels de la pharmacie. Je cite :
> Conflict of interest statement
> Declaration of interests JA and DP report receiving a grant to their research 
> institution from Novartis for the ORION 4 trial of inclisiran. AK reports 
> receiving grants for his institution from Abbott, Amgen, and Mylan; 
> consulting fees from AstraZeneca; honoraria from Sanofi and Pfizer; and is a 
> Data Safety Monitoring Board member of the Kowa PROMINENT trial. JS reports 
> receiving grants for his institution from Abbvie, Astra Zeneca, Bayer, 
> Bristol Myers Squibb, Pfizer, and Roche. RC reports a patent for a 
> statin-related myopathy genetic test licensed to University of Oxford from 
> Boston Heart Diagnostics (RC has waived any personal reward). All other 
> authors declare no competing interests.

Cette métaanalyse a été réalisée à partir d'articles facilement 
accessibles. J'imagine que vous allez proposer de les reprendre 
vous-même pour corriger le tir, si vous le jugez nécessaire et 
possible.